M
Massimo Massi-Benedetti
Researcher at University of Perugia
Publications - 28
Citations - 7772
Massimo Massi-Benedetti is an academic researcher from University of Perugia. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 21, co-authored 28 publications receiving 7389 citations.
Papers
More filters
Journal ArticleDOI
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more
TL;DR: Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified; mortality rates from heart failure did not differ between groups.
Journal ArticleDOI
Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes
Roman Hovorka,Valentina Canonico,Ludovic J. Chassin,Ulrich Haueter,Massimo Massi-Benedetti,Marco Orsini Federici,Thomas R. Pieber,Helga C. Schaller,Lukas Schaupp,Thomas Vering,Malgorzata E. Wilinska +10 more
TL;DR: Adapt nonlinear model predictive control is promising for the control of glucose concentration during fasting conditions in subjects with type 1 diabetes.
Journal ArticleDOI
A desktop guide to Type 2 diabetes mellitus
M. Aguilar,K. G. M. M. Alberti,Stephanie A. Amiel,J. Azzopardi,C. Berne,Rudy Bilous,Knut Borch-Johnsen,G. Cathelineau,P. V.M. Cromme,A. Dawson,R. Elphick,A Ericsson,D. R. Hadden,Robert J. Heine,Philip Home,I. Kalo,T. Kangas,Rüdiger Landgraf,T. Lauritzen,Massimo Massi-Benedetti,A. Mitrakou-Fanariotou,Thomas R. Pieber,A. Pruijs Brands,H. Schatz,Werner A. Scherbaum,A. Serhiyenko,J. Sieradzki,P. Swift,L. Uccioli,P. Van Crombrugge,W. H.J.M. Wientjens,M. T. Yilmaz,Hannele Yki-Järvinen +32 more
Journal ArticleDOI
Reduced Hypoglycemia Risk With Insulin Glargine A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes
Julio Rosenstock,George Dailey,Massimo Massi-Benedetti,Andreas Fritsche,Zhengning Lin,Alan Salzman +5 more
TL;DR: It is confirmed that insulin glargine given once daily reduces the risk of hypoglycemia compared with NPH insulin, which can facilitate more aggressive insulin treatment to a HbA(1c) target of < or =7.0% in patients with type 2 diabetes.
Journal ArticleDOI
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erland Erdmann,John A. Dormandy,Bernard Charbonnel,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,PROactive Investigators +6 more
TL;DR: In high-risk patients with type 2 diabetes and previous MI, pioglitazone significantly reduced the occurrence of fatal and nonfatal MI and ACS.